Mesquite TX 超重临床试验
6项针对 超重的研究正在 Mesquite及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
招募中3 期
- Southern Endocrinology Associates PA, Mesquite
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
招募中3 期
- Southern Endocrinology Associates, Mesquite
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
招募中3 期
- AURORA-1 Clinical Site, Mesquite
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
招募中3 期
- AURORA-2 Clinical Site, Mesquite
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
招募中2 期
- Southern Endocrinology Associates, Mesquite
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
招募中3 期
- Southern Endocrinology Associates PA, Mesquite
其他城市的 超重试验
- Houston, TX33 项研究
- San Antonio, TX33 项研究
- Chicago, IL28 项研究
- Orlando, FL25 项研究
- Las Vegas, NV23 项研究
- Miami, FL23 项研究
- Dallas, TX20 项研究
- Atlanta, GA20 项研究
- Jacksonville, FL19 项研究
- Washington, DC19 项研究
- New York City, NY19 项研究
- Austin, TX18 项研究
Mesquite的其他研究
数据来自 ClinicalTrials.gov，检索日期：2026年9月30日。每项研究自行设定入选标准，由研究团队决定谁能参与。